nach oben

09.04.2024 | REVIEW

In vivo manufacture and manipulation of CAR-T cells for better druggability

verfasst von: Rui Hou, Xiaoxue Zhang, Xu Wang, Xuan Zhao, Sijin Li, Zhangchun Guan, Jiang Cao, Dan Liu, Junnian Zheng, Ming Shi

Erschienen in: Cancer and Metastasis Reviews

Einloggen, um Zugang zu erhalten

Abstract

The current CAR-T cell therapy products have been hampered in their druggability due to the personalized preparation required, unclear pharmacokinetic characteristics, and unpredictable adverse reactions. Enabling standardized manufacturing and having clear efficacy and pharmacokinetic characteristics are prerequisites for ensuring the effective practicality of CAR-T cell therapy drugs. This review provides a broad overview of the different approaches for controlling behaviors of CAR-T cells in vivo. The utilization of genetically modified vectors enables in vivo production of CAR-T cells, thereby abbreviating or skipping the lengthy in vitro expansion process. By equipping CAR-T cells with intricately designed control elements, using molecule switches or small-molecule inhibitors, the control of CAR-T cell activity can be achieved. Moreover, the on–off control of CAR-T cell activity would yield potential gains in phenotypic remodeling. These methods provide beneficial references for the future development of safe, controllable, convenient, and suitable for standardized production of CAR-T cell therapy products.

Abi Hussein, H., et al. (2017). Global vision of druggability issues. Drug Discovery Today, 22, 404–415. https://doi.org/10.1016/j.drudis.2016.11.021CrossRef

Fauman, E. B., Rai, B. K., & Huang, E. S. (2011). Structure-based druggability assessment–Identifying suitable targets for small molecule therapeutics. Current opinion in Chemical Biology, 15, 463–468. https://doi.org/10.1016/j.cbpa.2011.05.020CrossRefPubMed

Owens, J. (2007). Determining druggability. Nature Reviews Drug Discovery, 6, 187. https://doi.org/10.1038/nrd2275CrossRef

Cheng, A. C., et al. (2007). Structure-based maximal affinity model predicts small-molecule druggability. Nature Biotechnology, 25, 71–75. https://doi.org/10.1038/nbt1273CrossRefPubMed

Vormittag, P., Gunn, R., Ghorashian, S., & Veraitch, F. S. (2018). A guide to manufacturing CAR T cell therapies. Current Opinion in Biotechnology, 53, 164–181. https://doi.org/10.1016/j.copbio.2018.01.025CrossRefPubMed

Watanabe, N., Mo, F., & McKenna, M. K. (2022). Impact of manufacturing procedures on CAR T cell functionality. Frontiers in Immunology, 13, 876339. https://doi.org/10.3389/fimmu.2022.876339CrossRefPubMedPubMedCentral

Abou-El-Enein, M., et al. (2021). Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discovery, 2, 408–422. https://doi.org/10.1158/2643-3230.Bcd-21-0084CrossRefPubMedPubMedCentral

Allen, E. S., et al. (2017). Autologous lymphapheresis for the production of chimeric antigen receptor T cells. Transfusion, 57, 1133–1141. https://doi.org/10.1111/trf.14003CrossRefPubMedPubMedCentral

Sun, W., Jiang, Z., Jiang, W., & Yang, R. (2022). Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence. Cancer Treatment and Research Communications, 33, 100638. https://doi.org/10.1016/j.ctarc.2022.100638CrossRefPubMed

10.

Torikai, H., et al. (2012). A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood, 119, 5697–5705. https://doi.org/10.1182/blood-2012-01-405365CrossRefPubMedPubMedCentral

11.

Grupp, S. A., et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. The New England Journal of Medicine, 368, 1509–1518. https://doi.org/10.1056/NEJMoa1215134CrossRefPubMedPubMedCentral

12.

Kochenderfer, J. N., et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood, 119, 2709–2720. https://doi.org/10.1182/blood-2011-10-384388CrossRefPubMedPubMedCentral

13.

Lamers, C. H., et al. (2013). Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: Clinical evaluation and management of on-target toxicity. Molecular therapy : The journal of the American Society of Gene Therapy, 21, 904–912. https://doi.org/10.1038/mt.2013.17CrossRefPubMed

14.

Barrett, D. M., Teachey, D. T., & Grupp, S. A. (2014). Toxicity management for patients receiving novel T-cell engaging therapies. Current Opinion in Pediatrics, 26, 43–49. https://doi.org/10.1097/mop.0000000000000043CrossRefPubMedPubMedCentral

15.

Daniels, K. G., et al. (2022). Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning. Science (New York, N.Y.).=, 378, 1194–1200. https://doi.org/10.1126/science.abq0225CrossRefPubMedPubMedCentral

16.

Alizadeh, D., et al. (2019). IL15 Enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunology Research, 7, 759–772. https://doi.org/10.1158/2326-6066.Cir-18-0466CrossRefPubMedPubMedCentral

17.

Amini, L., et al. (2022). Preparing for CAR T cell therapy: Patient selection, bridging therapies and lymphodepletion. Nature Reviews. Clinical Oncology, 19, 342–355. https://doi.org/10.1038/s41571-022-00607-3CrossRefPubMed

18.

Schwartz, R. H. (2003). T cell anergy. Annual Review of Immunology, 21, 305–334. https://doi.org/10.1146/annurev.immunol.21.120601.141110CrossRefPubMed

19.

Dropulić, B. (2011). Lentiviral vectors: Their molecular design, safety, and use in laboratory and preclinical research. Human Gene Therapy, 22, 649–657. https://doi.org/10.1089/hum.2011.058CrossRefPubMed

20.

Zhou, Q., et al. (2012). T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood, 120, 4334–4342. https://doi.org/10.1182/blood-2012-02-412973CrossRefPubMed

21.

Zhou, Q., et al. (2015). Exclusive transduction of human CD4+ T cells upon systemic delivery of CD4-targeted lentiviral vectors. Journal of immunology (Baltimore, Md. : 1950), 195, 2493–2501, https://doi.org/10.4049/jimmunol.1500956

22.

Pfeiffer, A., et al. (2018). In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome. EMBO Molecular Medicine, 10. https://doi.org/10.15252/emmm.201809158

23.

Ho, N., et al. (2022). In vivo generation of CAR T cells in the presence of human myeloid cells. Molecular therapy. Methods & Clinical Development, 26, 144–156. https://doi.org/10.1016/j.omtm.2022.06.004CrossRef

24.

Moço, P. D., Aharony, N., & Kamen, A. (2020). Adeno-associated viral vectors for homology-directed generation of CAR-T cells. Biotechnology Journal, 15, e1900286. https://doi.org/10.1002/biot.201900286CrossRefPubMed

25.

Wu, Z., Asokan, A., & Samulski, R. J. (2006). Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Molecular Therapy : The Journal of the American Society of Gene Therapy, 14, 316–327. https://doi.org/10.1016/j.ymthe.2006.05.009CrossRefPubMed

26.

Wang, J., et al. (2016). Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Research, 44, e30. https://doi.org/10.1093/nar/gkv1121CrossRefPubMed

27.

MacLeod, D. T., et al. (2017). Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. Molecular Therapy: The Journal of the American Society of Gene Therapy, 25, 949–961. https://doi.org/10.1016/j.ymthe.2017.02.005CrossRefPubMed

28.

Dai, X., et al. (2019). One-step generation of modular CAR-T cells with AAV-Cpf1. Nature Methods, 16, 247–254. https://doi.org/10.1038/s41592-019-0329-7CrossRefPubMedPubMedCentral

29.

Nawaz, W., et al. (2021). AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer Journal, 11, 119. https://doi.org/10.1038/s41408-021-00508-1CrossRefPubMedPubMedCentral

30.

Brady, J. M., Baltimore, D., & Balazs, A. B. (2017). Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Immunological Reviews, 275, 324–333. https://doi.org/10.1111/imr.12478CrossRefPubMedPubMedCentral

31.

Nyberg, W. A., et al. (2023). An evolved AAV variant enables efficient genetic engineering of murine T cells. Cell, 186, 446–460.e419. https://doi.org/10.1016/j.cell.2022.12.022CrossRefPubMedPubMedCentral

32.

Agarwal, S., Weidner, T., Thalheimer, F. B., & Buchholz, C. J. (2019). In vivo generated human CAR T cells eradicate tumor cells. Oncoimmunology, 8, e1671761. https://doi.org/10.1080/2162402x.2019.1671761CrossRefPubMedPubMedCentral

33.

Agarwal, S., et al. (2020). In vivo generation of CAR T cells selectively in human CD4(+) lymphocytes. Molecular therapy : The Journal of the American Society of Gene Therapy, 28, 1783–1794. https://doi.org/10.1016/j.ymthe.2020.05.005CrossRefPubMed

34.

Frank, A. M., et al. (2020). Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors. Blood Advances, 4, 5702–5715. https://doi.org/10.1182/bloodadvances.2020002229CrossRefPubMedPubMedCentral

35.

Huckaby, J. T., et al. (2021). Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells. Journal for Immunotherapy of Cancer, 9. https://doi.org/10.1136/jitc-2021-002737

36.

Mathur, D., Galvan, A. R., Green, C. M., Liu, K., & Medintz, I. L. (2023). Uptake and stability of DNA nanostructures in cells: A cross-sectional overview of the current state of the art. Nanoscale, 15, 2516–2528. https://doi.org/10.1039/d2nr05868eCrossRefPubMedPubMedCentral

37.

Tian, R., Shang, Y., Wang, Y., Jiang, Q. & Ding, B. (2023) DNA nanomaterials-based platforms for cancer immunotherapy. Small Methods, e2201518. https://doi.org/10.1002/smtd.202201518

38.

Smith, T. T., et al. (2017). In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nature Nanotechnology, 12, 813–820. https://doi.org/10.1038/nnano.2017.57CrossRefPubMedPubMedCentral

39.

Rurik, J. G., et al. (2022). CAR T cells produced in vivo to treat cardiac injury. Science (New York, N.Y.), 375, 91–96. https://doi.org/10.1126/science.abm0594CrossRefPubMed

40.

Zhao, G., Zhang, Y., Xu, C. F., & Wang, J. (2024). In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles. Science Bulletin, 69, 354–366. https://doi.org/10.1016/j.scib.2023.11.055CrossRefPubMed

41.

Kaech, S. M., Wherry, E. J., & Ahmed, R. (2002). Effector and memory T-cell differentiation: Implications for vaccine development. Nature Reviews. Immunology, 2, 251–262. https://doi.org/10.1038/nri778CrossRefPubMed

42.

Okła, K., Farber, D. L. & Zou, W. (2021). Tissue-resident memory T cells in tumor immunity and immunotherapy. The Journal of Experimental Medicine, 218. https://doi.org/10.1084/jem.20201605

43.

Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2012) Sorting through subsets: Which T-cell populations mediate highly effective adoptive immunotherapy? Journal of Immunotherapy (Hagerstown, Md. : 1997), 35, 651–660. https://doi.org/10.1097/CJI.0b013e31827806e6

44.

Hinrichs, C. S., et al. (2009). Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 106, 17469–17474. https://doi.org/10.1073/pnas.0907448106CrossRefPubMedPubMedCentral

45.

El Marabti, E., & Abdel-Wahab, O. (2023). Enhancing CD19 chimeric antigen receptor T cells through memory-enriched T cells. Clinical Cancer Research : An official Journal of the American Association for Cancer Research, 29, 694–696. https://doi.org/10.1158/1078-0432.Ccr-22-3232CrossRefPubMed

46.

Ghassemi, S., et al. (2018). Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunology Research, 6, 1100–1109. https://doi.org/10.1158/2326-6066.Cir-17-0405CrossRefPubMedPubMedCentral

47.

Agarwalla, P., et al. (2022). Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells. Nature Biotechnology, 40, 1250–1258. https://doi.org/10.1038/s41587-022-01245-xCrossRefPubMedPubMedCentral

48.

Yang, J., et al. (2022). Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: First-in-human clinical study. Blood Cancer Journal, 12, 104. https://doi.org/10.1038/s41408-022-00694-6CrossRefPubMedPubMedCentral

49.

Zhang, C., et al. (2022). Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia. Blood Cancer Journal, 12, 96. https://doi.org/10.1038/s41408-022-00688-4CrossRefPubMedPubMedCentral

50.

Wang, Y. L. et al. (2021). Web-based quantitative structure-activity relationship resources facilitate effective drug discovery. Topics in Current Chemistry (Cham), 379, 37. https://doi.org/10.1007/s41061-021-00349-3

51.

Neelakantan, H., et al. (2017). Structure-activity relationship for small molecule inhibitors of nicotinamide N-methyltransferase. Journal of Medicinal Chemistry, 60, 5015–5028. https://doi.org/10.1021/acs.jmedchem.7b00389CrossRefPubMed

52.

Ding, S., et al. (2019). Exploration of the structure-activity relationship and druggability of novel oxazolidinone-based compounds as Gram-negative antibacterial agents. Archiv der Pharmazie, 352, e1900129. https://doi.org/10.1002/ardp.201900129CrossRefPubMed

53.

Xue, T., et al. (2014). Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor. Journal of Medicinal Chemistry, 57, 7770–7791. https://doi.org/10.1021/jm501045eCrossRefPubMed

54.

Lu, J., & Jiang, G. (2022). The journey of CAR-T therapy in hematological malignancies. Molecular Cancer, 21, 194. https://doi.org/10.1186/s12943-022-01663-0CrossRefPubMedPubMedCentral

55.

Dimitri, A., Herbst, F., & Fraietta, J. A. (2022). Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Molecular Cancer, 21, 78. https://doi.org/10.1186/s12943-022-01559-zCrossRefPubMedPubMedCentral

56.

Morgan, M. A., Büning, H., Sauer, M., & Schambach, A. (2020). Use of cell and genome modification technologies to generate improved “Off-the-Shelf” CAR T and CAR NK Cells. Frontiers in Immunology, 11, 1965. https://doi.org/10.3389/fimmu.2020.01965CrossRefPubMedPubMedCentral

57.

Roselli, E., et al. (2021). 4–1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. Journal for Immunotherapy of Cancer, 9. https://doi.org/10.1136/jitc-2021-003354

58.

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England Journal of Medicine, 365, 725–733. https://doi.org/10.1056/NEJMoa1103849CrossRefPubMedPubMedCentral

59.

Flugel, C. L., et al. (2023). Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nature Reviews. Clinical Oncology, 20, 49–62. https://doi.org/10.1038/s41571-022-00704-3CrossRefPubMed

60.

Shanmugasundaram, U., et al. (2020). Pulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment. JCI Insight, 5. https://doi.org/10.1172/jci.insight.137858

61.

Mestermann, K., et al. (2019). The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Science Translational Medicine, 11. https://doi.org/10.1126/scitranslmed.aau5907

62.

Weber, E. W. et al. (2021). Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science (New York, N.Y.), 372. https://doi.org/10.1126/science.aba1786

63.

Preman, N. K., Barki, R. R., Vijayan, A., Sanjeeva, S. G. & Johnson, R. P. (2020). Recent developments in stimuli-responsive polymer nanogels for drug delivery and diagnostics: A review. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V., 157, 121–153. https://doi.org/10.1016/j.ejpb.2020.10.009

64.

Molina, M., et al. (2015). Stimuli-responsive nanogel composites and their application in nanomedicine. Chemical Society Reviews, 44, 6161–6186. https://doi.org/10.1039/c5cs00199dCrossRefPubMed

65.

Nguyen, N. T., et al. (2021). Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nature Nanotechnology, 16, 1424–1434. https://doi.org/10.1038/s41565-021-00982-5CrossRefPubMedPubMedCentral

66.

Huang, Z., et al. (2020). Engineering light-controllable CAR T cells for cancer immunotherapy. Science Advances, 6, eaay9209. https://doi.org/10.1126/sciadv.aay9209CrossRefPubMedPubMedCentral

67.

Tsien, R. Y. (2003). Imagining imaging's future. Nature reviews. Molecular Cell Biology, Suppl, Ss16–21.

68.

Miller, I. C., et al. (2021). Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. Nature Biomedical Engineering, 5, 1348–1359. https://doi.org/10.1038/s41551-021-00781-2CrossRefPubMedPubMedCentral

69.

Chen, Z., et al. (2021). Nanoengineered CAR-T biohybrids for solid tumor immunotherapy with microenvironment photothermal-remodeling strategy. Small (Weinheim an der Bergstrasse, Germany), 17, e2007494. https://doi.org/10.1002/smll.202007494CrossRefPubMed

70.

Thanou, M., & Gedroyc, W. (2013). MRI-guided focused ultrasound as a new method of drug delivery. Journal of Drug Delivery, 2013, 616197. https://doi.org/10.1155/2013/616197CrossRefPubMedPubMedCentral

71.

Piraner, D. I., Abedi, M. H., Moser, B. A., Lee-Gosselin, A., & Shapiro, M. G. (2017). Tunable thermal bioswitches for in vivo control of microbial therapeutics. Nature Chemical Biology, 13, 75–80. https://doi.org/10.1038/nchembio.2233CrossRefPubMed

72.

Jacob, P., Hirt, H., & Bendahmane, A. (2017). The heat-shock protein/chaperone network and multiple stress resistance. Plant Biotechnology Journal, 15, 405–414. https://doi.org/10.1111/pbi.12659CrossRefPubMedPubMedCentral

73.

Wu, Y., et al. (2021). Control of the activity of CAR-T cells within tumours via focused ultrasound. Nature Biomedical Engineering, 5, 1336–1347. https://doi.org/10.1038/s41551-021-00779-wCrossRefPubMedPubMedCentral

74.

Paszkiewicz, P. J., et al. (2016). Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. The Journal of Clinical Investigation, 126, 4262–4272. https://doi.org/10.1172/jci84813CrossRefPubMedPubMedCentral

75.

Wang, Q., et al. (2021). A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells. Cellular Immunology, 363, 104342. https://doi.org/10.1016/j.cellimm.2021.104342CrossRefPubMed

76.

Philip, B., et al. (2014). A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood, 124, 1277–1287. https://doi.org/10.1182/blood-2014-01-545020CrossRefPubMed

77.

Gargett, T., & Brown, M. P. (2014). The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Frontiers in Pharmacology, 5, 235. https://doi.org/10.3389/fphar.2014.00235CrossRefPubMedPubMedCentral

78.

Guercio, M. et al. (2021). Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-cell malignancies. Frontiers in Immunology, 12, 755639. https://doi.org/10.3389/fimmu.2021.755639

79.

Diaconu, I., et al. (2017). Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells. Molecular therapy : The journal of the American Society of Gene Therapy, 25, 580–592. https://doi.org/10.1016/j.ymthe.2017.01.011CrossRefPubMed

80.

Roybal, K. T., et al. (2016). Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell, 167, 419-432.e416. https://doi.org/10.1016/j.cell.2016.09.011CrossRefPubMedPubMedCentral

81.

Zheng, Y., Nandakumar, K. S., & Cheng, K. (2021). Optimization of CAR-T cell-based therapies using small-molecule-based safety switches. Journal of Medicinal Chemistry, 64, 9577–9591. https://doi.org/10.1021/acs.jmedchem.0c02054CrossRefPubMed

82.

Ma, J. S., et al. (2016). Versatile strategy for controlling the specificity and activity of engineered T cells. Proceedings of the National Academy of Sciences of the United States of America, 113, E450-458. https://doi.org/10.1073/pnas.1524193113CrossRefPubMedPubMedCentral

83.

Cao, Y., et al. (2016).Design of switchable chimeric antigen receptor T cells targeting breast cancer. Angewandte Chemie (International ed. in English), 55, 7520–7524. https://doi.org/10.1002/anie.201601902

84.

Kim, M. S., et al. (2015). Redirection of genetically engineered CAR-T cells using bifunctional small molecules. Journal of the American Chemical Society, 137, 2832–2835. https://doi.org/10.1021/jacs.5b00106CrossRefPubMed

85.

Qi, J., et al. (2020). Chemically programmable and switchable CAR-T therapy. Angewandte Chemie (International ed in English), 59, 12178–12185. https://doi.org/10.1002/anie.202005432CrossRefPubMed

86.

Choi, J., Chen, J., Schreiber, S. L., & Clardy, J. (1996). Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science (New York, N.Y.)., 273, 239–242. https://doi.org/10.1126/science.273.5272.239CrossRefPubMed

87.

Wu, C. Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015). Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science (New York, N.Y.), 350, aab4077. https://doi.org/10.1126/science.aab4077CrossRefPubMed

88.

Leung, W. H., et al. (2019) Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization. JCI Insight, 5. https://doi.org/10.1172/jci.insight.124430

89.

Bayle, J. H., et al. (2006). Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chemistry & Biology, 13, 99–107. https://doi.org/10.1016/j.chembiol.2005.10.017CrossRef

90.

Blake, S., Hughes, T. P., Mayrhofer, G., & Lyons, A. B. (2008). The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clinical Immunology (Orlando, Fla.)., 127, 330–339. https://doi.org/10.1016/j.clim.2008.02.006CrossRefPubMed

91.

Allen, G. M., et al. (2022). Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science (New York, N.Y.), 378, eaba1624. https://doi.org/10.1126/science.aba1624CrossRefPubMed

92.

Lim, W. A. (2022). The emerging era of cell engineering: Harnessing the modularity of cells to program complex biological function. Science (New York N.Y.), 378, 848–852. https://doi.org/10.1126/science.add9665CrossRefPubMed

93.

Grosskopf, A. K., et al. (2022). Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. Science Advances, 8, eabn8264. https://doi.org/10.1126/sciadv.abn8264CrossRefPubMedPubMedCentral

94.

Huang, X., et al. (2021). DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation. Nature Nanotechnology, 16, 214–223. https://doi.org/10.1038/s41565-020-00813-zCrossRefPubMed

95.

Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014). Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood, 123, 2625–2635. https://doi.org/10.1182/blood-2013-11-492231CrossRefPubMedPubMedCentral

96.

Hamieh, M., et al. (2019). CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature, 568, 112–116. https://doi.org/10.1038/s41586-019-1054-1CrossRefPubMedPubMedCentral

97.

Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer Journal, 11, 69. https://doi.org/10.1038/s41408-021-00459-7CrossRefPubMedPubMedCentral

98.

Martinez, M., & Moon, E. K. (2019). CAR T cells for solid tumors: New strategies for finding, infiltrating, and surviving in the tumor microenvironment. Frontiers in Immunology, 10, 128. https://doi.org/10.3389/fimmu.2019.00128CrossRefPubMedPubMedCentral

99.

Miao, L., Zhang, Z., Ren, Z., & Li, Y. (2021). Reactions related to CAR-T cell therapy. Frontiers in Immunology, 12, 663201. https://doi.org/10.3389/fimmu.2021.663201CrossRefPubMedPubMedCentral

100.

Totzeck, M., Michel, L., Lin, Y., Herrmann, J., & Rassaf, T. (2022). Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. European Heart Journal, 43, 1928–1940. https://doi.org/10.1093/eurheartj/ehac106CrossRefPubMedPubMedCentral

101.

Savoldo, B., et al. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. The Journal of Clinical Investigation, 121, 1822–1826. https://doi.org/10.1172/jci46110CrossRefPubMedPubMedCentral

102.

Kalos, M., et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine, 3, 95ra73.CrossRefPubMedPubMedCentral

103.

Pegram, H. J., et al. (2012). Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood, 119, 4133–4141. https://doi.org/10.1182/blood-2011-12-400044CrossRefPubMedPubMedCentral

104.

Choe, J. H. et al., (2021). SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Science Translational Medicine, 13. https://doi.org/10.1126/scitranslmed.abe7378

105.

Wang, Z., et al. (2022). 3D-organoid culture supports differentiation of human CAR(+) iPSCs into highly functional CAR T cells. Cell Stem Cell, 29, 515-527.e518. https://doi.org/10.1016/j.stem.2022.02.009CrossRefPubMedPubMedCentral

106.

López-Cantillo, G., Urueña, C., Camacho, B. A., & Ramírez-Segura, C. (2022). CAR-T cell performance: How to improve their persistence? Frontiers in Immunology, 13, 878209. https://doi.org/10.3389/fimmu.2022.878209CrossRefPubMedPubMedCentral

107.

Zhao, K., et al. (2023). The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice. Frontiers in Immunology, 14, 1101769. https://doi.org/10.3389/fimmu.2023.1101769CrossRefPubMedPubMedCentral

108.

Kasakovski, D., Xu, L., & Li, Y. (2018). T cell senescence and CAR-T cell exhaustion in hematological malignancies. Journal of Hematology & Oncology, 11, 91. https://doi.org/10.1186/s13045-018-0629-xCrossRef

109.

Napoleon, J. V., Zhang, B., Luo, Q., Srinivasarao, M., & Low, P. S. (2022). Design, synthesis, and targeted delivery of an immune stimulant that selectively reactivates exhausted CAR T cells. Angewandte Chemie (International ed. in English), 61, e202113341. https://doi.org/10.1002/anie.202113341CrossRefPubMed

110.

Zebley, C. C., & Youngblood, B. (2021). CAR T cells need a pitstop to win the race. Cancer Cell, 39, 756–758. https://doi.org/10.1016/j.ccell.2021.05.011CrossRefPubMed

111.

Tantalo, D. G., et al. (2021). Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. Journal ForImmunotherapy of Cancer, 9. https://doi.org/10.1136/jitc-2021-002555

112.

Soerens, A. G., et al. (2023). Functional T cells are capable of supernumerary cell division and longevity. Nature, 614, 762–766. https://doi.org/10.1038/s41586-022-05626-9CrossRefPubMed

Titel: In vivo manufacture and manipulation of CAR-T cells for better druggability
verfasst von: Rui Hou
Xiaoxue Zhang
Xu Wang
Xuan Zhao
Sijin Li
Zhangchun Guan
Jiang Cao
Dan Liu
Junnian Zheng
Ming Shi
Publikationsdatum: 09.04.2024
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-024-10185-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

In vivo manufacture and manipulation of CAR-T cells for better druggability

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie